Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Hereditary Cancer in Clinical Practice
Published in: Hereditary Cancer in Clinical Practice 1/2014

Open Access 01-12-2014 | Research

Familial testicular germ cell tumor: no associated syndromic pattern identified

Authors: Christine M Mueller, Larissa A Korde, Mary L McMaster, June A Peters, Gennady Bratslavsky, Rissah J Watkins, Alex Ling, Christian P Kratz, Eric A Wulfsberg, Philip S Rosenberg, Mark H Greene

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2014

Login to get access

Abstract

Background

Testicular germ cell tumor (TGCT) is the most common malignancy in young men. Familial clustering, epidemiologic evidence of increased risk with family or personal history, and the association of TGCT with genitourinary (GU) tract anomalies have suggested an underlying genetic predisposition. Linkage data have not identified a rare, highly-penetrant, single gene in familial TGCT (FTGCT) cases. Based on its association with congenital GU tract anomalies and suggestions that there is an intrauterine origin to TGCT, we hypothesized the existence of unrecognized dysmorphic features in FTGCT.

Methods

We evaluated 38 FTGCT individuals and 41 first-degree relatives from 22 multiple-case families with detailed dysmorphology examinations, physician-based medical history and physical examination, laboratory testing, and genitourinary imaging studies.

Results

The prevalence of major abnormalities and minor variants did not significantly differ between either FTGCT individuals or their first-degree relatives when compared with normal population controls, except for tall stature, macrocephaly, flat midface, and retro-/micrognathia. However, these four traits were not manifest as a constellation of features in any one individual or family. We did detect an excess prevalence of the genitourinary anomalies cryptorchidism and congenital inguinal hernia in our population, as previously described in sporadic TGCT, but no congenital renal, retroperitoneal or mediastinal anomalies were detected.

Conclusions

Overall, our study did not identify a constellation of dysmorphic features in FTGCT individuals, which is consistent with results of genetic studies suggesting that multiple low-penetrance genes are likely responsible for FTGCT susceptibility.
Literature
1.
Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW: Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, 97: 1407–1427. 10.1093/jnci/dji289CrossRefPubMed
2.
Dong C, Hemminki K: Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families. Int J Cancer 2001, 92: 144–150. 10.1002/1097-0215(200102)9999:9999<::AID-IJC1147>3.0.CO;2-CCrossRefPubMed
3.
Hemminki K, Li X: Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. Br J Cancer 2004, 90: 1765–1770. 10.1038/sj.bjc.6601714CrossRefPubMedPubMedCentral
4.
Giambartolomei C, Mueller CM, Greene MH, Korde LA: A mini-review of familial ovarian germ cell tumors: an additional manifestation of the familial testicular germ cell tumor syndrome. Cancer Epidemiol 2009, 33: 31–36. 10.1016/j.canep.2009.04.015CrossRefPubMedPubMedCentral
5.
Mai PL, Chen BE, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MAS, Bodrogi I, Geczi L, Olah E, Heimdal K, Fossa SD, Nathanson KL, Korde L, Easton DF, Dudakia D, Huddart R, Stratton MR, Bishop DT, Rapley EA, Greene MH: Younger age-at-diagnosis for familial malignant germ cell tumor. Fam Cancer 2009, 8: 451–456. 10.1007/s10689-009-9264-6CrossRefPubMedPubMedCentral
6.
Mai PL, Friedlander M, Tucker K, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Bonaiti-Pellie C, Heidenreich A, Albers P, Bodrogi I, Geczi L, Olah E, Daly PA, Guilford P, Fossa SD, Heimdal K, Liubchenko L, Tjulandin SA, Stoll H, Weber W, Easton DF, Dudakia D, Huddart R, Stratton MR, Einhorn L, Korde L, Nathanson KL, et al.: The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol 2010, 28: 492–499. 10.1016/j.urolonc.2008.10.004CrossRefPubMed
7.
Crockford GP, Linger R, Hockley S, Dudakia D, Johnson L, Huddart R, Tucker K, Friedlander M, Phillips K, Hogg D, Jewett MAS, Lohynska R, Daugaard G, Richard S, Chompret A, Bonaiti-Pellie C, Heidenreich A, Albers P, Olah E, Geczi L, Bodrogi I, Ormiston WJ, Daly PA, Guildford P, Fossa SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H, Weber W, et al.: Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet 2006, 15: 443–451.CrossRefPubMed
8.
Heimdal K, Olsson H, Tretli S, Fossa SD, Borresen AL, Bishop DT: A segregation analysis of testicular cancer based on Norwegian and Swedish families. Br J Cancer 1997, 75: 1084–1087. 10.1038/bjc.1997.185CrossRefPubMedPubMedCentral
9.
10.
Rapley EA, Crockford GP, Teare D, Biggs P, Seal S, Barfoot R, Edwards S, Hamoudi R, Heimdal K, Fossa SD, Tucker K, Donald J, Collins F, Friedlander M, Hogg D, Goss P, Heidenreich A, Ormiston W, Daly PA, Forman D, Oliver TD, Leahy M, Huddart R, Cooper CS, Bodmer JG, Easton DF, Stratton MR, Bishop DT: Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet 2000, 24: 197–200. 10.1038/72877CrossRefPubMed
11.
Rapley EA, Crockford GP, Easton DF, Stratton MR, Bishop DT, International Testicular Cancer Linkage Consortium: Localisation of susceptibility genes for familial testicular germ cell tumour. APMIS 2003, 111: 128–133. 10.1034/j.1600-0463.2003.11101171.xCrossRefPubMed
12.
Mueller CM, Korde L, Katki HA, Rosenberg PS, Peters JA, Greene MH: Constitutional cytogenetic analysis in men with hereditary testicular germ cell tumor: no evidence of disease-related abnormalities. Cancer Epidemiol Biomarkers Prev 2007, 16: 2791–2794. 10.1158/1055-9965.EPI-07-0521CrossRefPubMedPubMedCentral
13.
Horvath A, Korde L, Greene MH, Libe R, Osorio P, Faucz FR, Raffin-Sanson ML, Tsang KM, Drori-Herishanu L, Patronus Y, Remmers EF, Nikita ME, Moran J, Greene J, Nesterova M, Merino M, Bertherat J, Stratakis CA: Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors. Cancer Res 2009, 69: 5301–5306. 10.1158/0008-5472.CAN-09-0884CrossRefPubMedPubMedCentral
14.
Linger R, Dudakia D, Huddart R, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MAS, Lohynska R, Daugaard G, Richard S, Chompret A, Stoppa-Lyonnet D, Bonaiti-Pellie C, Heidenreich A, Albers P, Olah E, Geczi L, Bodrogi I, Daly PA, Guilford P, Fossa SD, Heimdal K, Tijulandin SA, Liubchenko L, Stoll H, Weber W, Einhorn L, McMaster M, Korde L, et al.: Analysis of the DND1 gene in men with sporadic and familial germ cell tumors. Genes Chromosomes Cancer 2008, 47: 247–252. 10.1002/gcc.20526CrossRefPubMedPubMedCentral
15.
Nathanson KL, Kanetsky PA, Hawes R, Vaughn DJ, Letrero R, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Chompret A, Bonaiti-Pellie C, Heidenreich A, Olah E, Geczi L, Godrogi I, Ormiston WJ, Daly PA, Oosterhuis JW, Gillis AJ, Looijenga LH, Guilford P, Fossa SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H, et al.: The Y deletion gr / gr and susceptibility to testicular germ cell tumor. Am J Hum Genet 2005, 77: 1034–1043. 10.1086/498455CrossRefPubMedPubMedCentral
16.
Kanetsky PA, Mitra N, Vardhanabhuti S, Li M, Vaughn DJ, Letrero R, Ciosek SL, Doody DR, Smith LM, Weaver J, Albano A, Chen C, Starr JR, Rader DJ, Godwin AK, Reilly MP, Hakonarson H, Schwartz SM, Nathanson KL: Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 2009, 41: 811–815. 10.1038/ng.393CrossRefPubMedPubMedCentral
17.
Kanetsky PA, Mitra N, Vardhanabhuti S, Vaughn DJ, Li M, Ciosek SL, Letrero R, D’Andrea K, Vaddi M, Doody DR, Weaver J, Chen C, Starr JR, Hakonarson H, Rader DJ, Godwin AK, Reilly MP, Schwartz SM, Nathanson KL: A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Hum Molec Genetics 2011,20(15):3109–3117. 10.1093/hmg/ddr207CrossRef
18.
Rapley EA, Turnbull C, Al Olama AA, Dermitzakis ET, Linger R, Huddart RA, Renwick A, Hughes D, Hines S, Seal S, Morrison J, Nsengimana J, Deloukas P, Rahman N, Bishop DT, Easton DF, Stratton MR, UK Testicular Cancer Collaboration: A genome-wide association study of testicular germ cell tumor. Nat Genet 2009, 41: 807–810. 10.1038/ng.394CrossRefPubMedPubMedCentral
19.
Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Ricketts M, Linger R, Nsengimana J, Deloukas P, Huddart RA, Bishop DT, Easton DF, Stratton MR, Rahman N: Variants near DMRT1 , TERT , and ATF7IP are associated with testicular germ cell cancer. Nat Genet 2010, 42: 604–607. 10.1038/ng.607CrossRefPubMedPubMedCentral
20.
Kratz CP, Han SS, Rosenberg PS, Berndt SI, Burdett L, Yeager M, Korde LA, Mai PL, Pfeiffer R, Greene MH: Variants in or near KITLG , BAK1 , DMRT1 and TERT - CLPTM1L predispose to familial testicular germ cell tumor. J Med Genet 2011, 48: 473–476. 10.1136/jmedgenet-2011-100001CrossRefPubMedPubMedCentral
21.
Chung CC, Kanetsky PA, Wang Z, Hildebrandt MAT, Koster R, Skotheim RI, Kratz CP, Turnbull C, Cortessis VK, Bakken AC, Bishop DT, Cook MB, Erickson RL, Fossa SD, Jacobs KB, Korde LA, Kraggerud SM, Lothe RA, Loud JT, Rahman N, Skinner EC, Thomas DC, Wu X, Yeager M, Schumacher FR, Greene MH, Schwartz SM, McGlynn KA, Chanock SJ, Nathanson KL: Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet 2013, 45: 680–685. 10.1038/ng.2634CrossRefPubMedPubMedCentral
22.
Schumacher FR, Wang Z, Skotheim RI, Koster R, Chung CC, Hildebrandt MAT, Kratz CP, Bishop DT, Casey G, Cook MB, Erickson RL, Fossa SD, Gjessing HK, Greene MH, Jacobs KB, Kanetsky PA, Kolonel LN, Loud JT, Korde LA, Marchand LL, Lewinger JP, Lothe RA, Pike MC, Rahman N, Rubertone MV, Schwartz SM, Siegmund KD, Skinner EC, Thomas DC, Turnbull C, et al.: Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. Hum Mol Genet 2013,22(13):2748–2753. 10.1093/hmg/ddt109CrossRefPubMedPubMedCentral
23.
Ruark E, Seal S, McDonald H, Zhang F, Elliot A, Perdeaux E, Rapley E, Eeles R, Peto J, Kote-Jarai Z, Muir K, Nsengimana J, Shipley J, Bishop DT, Stratton MR, Easton DF, Huddart RA, Rahman N, Turnbull C: Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14 . Nature Genet 2013,45(6):686–689. 10.1038/ng.2635CrossRefPubMed
24.
Mirabello L, Savage SA, Korde L, Gadalla SM, Greene MH: LINE-1 methylation is inherited in familial testicular cancer kindreds. BMC Med Genet 2010, 11: 77.CrossRefPubMedPubMedCentral
25.
Garner MJ, Turner MC, Ghadirian P, Krewski D: Epidemiology of testicular cancer: an overview. Int J Cancer 2005, 116: 331–339. 10.1002/ijc.21032CrossRefPubMed
26.
Lutke Holzik MF, Rapley EA, Hoekstra HJ, Sleijfer DT, Nolte IM, Sijmons RH: Genetic predisposition to testicular germ-cell tumours. Lancet Oncol 2004, 5: 363–371. 10.1016/S1470-2045(04)01493-7CrossRefPubMed
27.
Holt PJ, Adshead JM, Filiadis I, Christmas TJ: Retroperitoneal anomalies in men with testicular germ cell tumours. B J U Int 2007, 99: 344–346. 10.1111/j.1464-410X.2006.06555.xCrossRef
28.
Mehes K, Szule E, Torzsok F, Meggyessy V: Supernumerary nipples and urologic malignancies. Cancer Genet Cytogenet 1987, 24: 185–188. 10.1016/0165-4608(87)90097-5CrossRefPubMed
29.
Skakkebaek NE, Rajpert-De Meyts E, Main KM: Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 2001, 16: 972–978. 10.1093/humrep/16.5.972CrossRefPubMed
30.
Skakkebaek NE, Holm M, Hoei-Hansen C, Jorgensen N, Rajpert-DeMeyts E: Association between testicular dysgenesis syndrome (TDS) and testicular neoplasia: evidence from 20 adult patients with signs of maldevelopment of the testis. APMIS 2003, 111: 1–9. 10.1034/j.1600-0463.2003.11101031.xCrossRefPubMed
31.
Lutke Holzik MF, Sijmons RH, Sleijfer DT, Sonneveld DJ, Hoekstra-Weebers JE, van Echten-Arends J, Hoekstra HJ: Syndromic aspects of testicular carcinoma. Cancer 2003, 97: 984–992. 10.1002/cncr.11155CrossRefPubMed
32.
Merks JH, van Karnebeek CD, Caron HN, Hennekam RC: Phenotypic abnormalities: terminology and classification. Am J Med Genet Part A 2003, 123A: 211–230. 10.1002/ajmg.a.20249CrossRefPubMed
33.
Merks JH, Ozgen HM, Koster J, Zwinderman AH, Caron HN, Hennekam RC: Prevalence and patterns of morphological abnormalities in patients with childhood cancer. JAMA 2008, 299: 61–69.CrossRefPubMed
34.
Korde LA, Premkumar A, Mueller C, Rosenberg P, Soho C, Bratslavsky G, Greene MH: Increased prevalence of testicular microlithiasis in men with familial testicular cancer and their relatives. Br J Cancer 2008, 99: 1748–1753. 10.1038/sj.bjc.6604704CrossRefPubMedPubMedCentral
35.
Aase JM: Diagnostic Dysmorphology. New York: Springer; 1990:320.
36.
Hall JG, Allanson JE, Gripp KW, Slavotinek AM: Handbook of Physical Measurements. New York: Oxford University Press; 2007:520.
37.
Merks JH, Ozgen HM, Cluitmans TL, van der Burg-van Rijn JM, Cobben JM, van Leeuwen FE, Hennekam RC: Normal values for morphological abnormalities in school children. Am J Med Genet Part A 2006, 140A: 2091–2109. 10.1002/ajmg.a.31355CrossRef
38.
39.
Barthold JS, Gonzalez R: The epidemiology of congenital cryptorchidism, testicular ascent, and orchiopexy. J Urol 2003, 170: 2396–2401. 10.1097/01.ju.0000095793.04232.d8CrossRefPubMed
40.
Berkowitz GS, Lapinski RH, Gazella JG, Dolgin SE, Bodian CA, Holzman IR: Prevalence and natural history of cryptorchidism. Pediatrics 1993, 92: 44–49.PubMed
41.
42.
Decter RM: Renal duplication and fusion anomalies. Pediatr Clin North Am 1997, 44: 1323–1341. 10.1016/S0031-3955(05)70559-9CrossRefPubMed
43.
Hunziker M, Mohanan N, Menezes M, Puri P: Prevalence of duplex collecting systems in familial vesicoureteral reflux. Pediatr Surg Int 2010, 26: 115–117. 10.1007/s00383-009-2516-6CrossRefPubMed
Metadata
Title
Familial testicular germ cell tumor: no associated syndromic pattern identified
Authors
Christine M Mueller
Larissa A Korde
Mary L McMaster
June A Peters
Gennady Bratslavsky
Rissah J Watkins
Alex Ling
Christian P Kratz
Eric A Wulfsberg
Philip S Rosenberg
Mark H Greene
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2014
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/1897-4287-12-3

Other articles of this Issue 1/2014

Hereditary Cancer in Clinical Practice 1/2014 Go to the issue

Case report

Neurofibromatosis type I with breast cancer: not only for women!

Research

Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers

Research

Colorectal cancer and self-reported tooth agenesis

Research

Sequence-based detection of mutations in cadherin 1 to determine the prevalence of germline mutations in patients with invasive lobular carcinoma of the breast

Research

Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada

Research

Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Medellín, Colombia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits